Monoclonal Antibody Library Production via Proteome Array Screening

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for producing antibodies are costly and time-consuming, and there is a need for high-throughput production of highly specific antibodies that are reproducible and cost-effective.

Innovation Solution

The development of a library of antibodies produced by the same platform, where a significant percentage are monospecific, monoclonal, and IgG antibodies with similar binding affinities, capable of binding to native forms of target proteins, using methods that include immunizing animals with a wide range of antigens, isolating antibody-generating cells, and screening with human proteome arrays to select monospecific antibodies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If traditional methods are used to produce antibodies, then antibody quality can be maintained, but production time and cost increase significantly

Engineering Contradiction:
Improveproduction throughputVSAvoidproduction time
Core Design Contradiction:
ProductivityVSLoss of time

Solution Approach 1:

The patent segments the antibody production process into modular components: (1) immunizing animals with antigen libraries, (2) isolating antibody-generating cells, (3) screening with proteome arrays, and (4) selecting monospecific antibodies. This segmentation enables parallel processing and high-throughput production while maintaining quality through systematic evaluation at each stage.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent performs preliminary actions by pre-screening antibody-generating cells against human proteome arrays before final selection. This preliminary screening identifies monosspecific antibodies early in the process, eliminating the need for time-consuming later-stage testing and significantly reducing overall production time while ensuring high specificity.

Inventive Principle:
Principle #10Preliminary action

2Reliability

If traditional antibody production methods are used, then specific antibodies can be obtained, but the process is costly and time-consuming

Engineering Contradiction:
Improveantibody specificityVSAvoidproduction cost
Core Design Contradiction:
ReliabilityVSEase of manufacture

Solution Approach 1:

The patent creates a universal platform that can produce antibodies against multiple targets simultaneously using the same immunization and screening protocol. The human proteome array serves as a universal screening tool that can identify monosspecific antibodies for any protein target, eliminating the need for separate, target-specific production protocols and reducing overall cost.

Inventive Principle:
Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent uses proteome arrays as copies of the human proteome that can be screened simultaneously against many antibody candidates. This copying approach allows parallel evaluation of antibody specificity against multiple proteins without requiring separate physical proteins for each target, significantly reducing material costs and production time.

Inventive Principle:
Principle #26Copying

3Productivity

If high-throughput production methods are implemented, then production speed increases, but reproducibility and quality control become more difficult

Engineering Contradiction:
Improveproduction speedVSAvoidbinding affinity consistency
Core Design Contradiction:
ProductivityVSManufacturing precision

Solution Approach 1:

The patent implements feedback mechanisms through systematic evaluation of antibody binding affinity using proteome arrays. Each antibody candidate is screened against multiple protein targets, and the binding affinity data is used to feedback-select only those antibodies that meet predetermined criteria for monospecificity and consistent affinity, ensuring quality control at high throughput.

Inventive Principle:
Principle #23Feedback

Solution Approach 2:

The patent standardizes production parameters including immunization protocols, antibody isolation conditions, and screening criteria to ensure reproducibility. By controlling key parameters such as antigen concentration, incubation conditions, and selection thresholds, the method maintains consistent binding affinity across high-throughput produced antibodies while scaling up production speed.

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentEP2582862B1Methods and systems for generating, validating and using monoclonal antibodies
Publication Date: 2016.04.13 CDI LAB
  • EP2582862B1 patent drawingFigure 1A
  • EP2582862B1 patent drawingFigure 1B
  • EP2582862B1 patent drawingFigure 2

AI summary

Provided herein is a library of antibodies, wherein the library of antibodies can comprise a plurality of monoclonal, monospecific, or immunoprecipitating antibodies. Also provided herein is a method for producing and using the library of antibodies.